MAIA Biotechnology, Inc.
(NYSE Amex Equities : MAIA)

( )
MAIA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.45%171.140.0%$784.22m
AMGNAmgen, Inc. 0.43%248.361.5%$592.28m
VRTXVertex Pharmaceuticals, Inc. 1.66%298.831.9%$438.24m
GILDGilead Sciences, Inc. 0.65%62.001.0%$379.78m
REGNRegeneron Pharmaceuticals, Inc. -1.35%622.152.6%$351.29m
NVAXNovavax, Inc. -29.64%40.2875.7%$335.10m
SNSSSunesis Pharmaceuticals, Inc. -12.15%3.470.7%$242.57m
ILMNIllumina, Inc. -3.67%214.803.3%$229.68m
BIIBBiogen, Inc. 0.01%217.591.8%$197.59m
BNTXBioNTech SE -7.14%157.210.0%$155.97m
GOVXGeoVax Labs, Inc. -0.35%2.860.0%$145.88m
CRSPCRISPR Therapeutics AG -7.69%75.130.6%$117.81m
PLRXPliant Therapeutics, Inc. 11.19%21.160.0%$108.38m
RYTMRhythm Pharmaceuticals, Inc. 7.19%22.650.0%$105.42m
BMRNBioMarin Pharmaceutical, Inc. 0.00%95.704.2%$98.26m

Company Profile

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company?s lead product THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on 3rd August, 2018 and is headquartered in Chicago.